Case Studies: Stahl's Essential Psychopharmacology: CME Information

Release/Expiration Dates

Original release date: May 1, 2011

CME credit expiration date: April 30, 2014. (CNE credit expires April 30, 2013). If either of these dates has passed, please contact NEI for updated information.


This book is a series of case studies in psychiatric disorders, all adapted from real practice, that provide a glimpse into what cases look like after the first consultation and over time, living through the treatments that work, the treatments that do not work, the mistakes, and the lessons to be learned.

Target Audience

This activity has been developed for prescribers specializing in psychiatry. There are no prerequisites for this activity. Health care providers in all specialties who are interested in psychopharmacology, especially primary care physicians, nurses, nurse practitioners, psychologists, and pharmacists, are welcome for advanced study.

Statement of Need

The content of this educational activity was determined by critical analysis of activity feedback, expert faculty assessment, literature review, and new medical knowledge, which revealed the following unmet needs:

  • Mental disorders are highly prevalent and carry substantial burden that can be alleviated through treatment; unfortunately, many patients with mental disorders do not receive treatment or receive suboptimal treatment

  • There is a documented gap between evidence-based practice guidelines and actual care in clinical practice for patients with mental illnesses

  • This gap is due at least in part to lack of clinician confidence and knowledge in terms of appropriate usage of the diagnostic and treatment tools available to them

In order to improve outcomes for patients with psychiatric disorders, NEI will provide education regarding the following as one means to address clinician performance deficits with respect to diagnosis and treatment of mental disorders

  • Diagnostic strategies that can aid in the identification and differential diagnosis of patients with psychiatric illness

  • Effective clinical strategies for monitoring and treating psychiatric patients

  • New scientific evidence that is most likely to affect clinical practice

Learning Objectives

After completing this activity, participants should be better able to:

  • Diagnose patients presenting with psychiatric symptoms according to best practice standards

  • Implement evidence-based psychiatric treatment strategies designed to maximize adherence and patient outcomes

  • Integrate novel treatment approaches into clinical practice according to best practice guidelines

  • Assess treatment effectiveness and make adjustments as needed to improve patient outcomes

Accreditation and Credit Designation Statements

The Neuroscience Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Neuroscience Education Institute designates this enduring material for a maximum of 67.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Society for the Advancement of Pharmacotherapy is approved by the American Psychological Association to sponsor continuing education for psychologists. The American Society for the Advancement of Pharmacotherapy maintains responsibility for this program and its content.

The American Society for the Advancement of Pharmacotherapy designates this program for 67.0 CE credits for psychologists.

This continuing nursing education activity has been submitted for approval to ANA-MAINE, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Note to Physician Assistants: the AAPA accepts AMA PRA Category I Credit™ from organizations accredited by the ACCME.

Also available will be a certificate of participation for completing this activity.

Activity Instructions

This CME activity is in the form of a printed monograph and incorporates instructional design to enhance your retention of the information and pharmacological concepts that are being presented. You are advised to go through each case from beginning to end, including the brief tutorial at the end of each case, and then complete the posttest and activity evaluation. The estimated time for completion of this activity is 67 hours.

Instructions for CME Credit

To receive a certificate of CME credit or participation, please complete the posttest and commitment-to-change questions along with the activity evaluation, available online only at “Book”). If a passing score of 70% or more is attained (required to receive credit), you can immediately print your certificate. There is a fee for CME credits for this activity (waived for NEI members).

NEI Disclosure Policy

It is the policy of the Neuroscience Education Institute to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. The Neuroscience Education Institute takes responsibility for the content, quality, and scientific integrity of this CME activity.

All faculty participating in any NEI-sponsored educational activity and all individuals in a position to influence or control content development are required by NEI to disclose to the activity audience any financial relationships or apparent conflicts of interest that may have a direct bearing on the subject matter of the activity. Although potential conflicts of interest are identified and resolved prior to the activity, it remains for the audience to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.

Individual Disclosure Statements


Stephen M. Stahl, MD, PhD

Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine

Honorary Visiting Senior Fellow, University of Cambridge, UK

Grant/Research: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, Dainippon Sumitomo, Forest, Lilly, Lundbeck, Novartis, Pamlab, Pfizer, Pfizer Canada, Pharmasquire, sanofi-aventis, Schering-Plough, Sepracor, Shire, Wyeth

Consultant/Advisor: Allergan, Alkermes, Arena, AstraZeneca, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Covance, Cypress Bioscience, Dainippon Sumitomo, Eisai, Forest, GenOmind, GlaxoSmith Kline, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Marinus, MEDACorp/Leerink Swann, Meiji, Merck, Neuronetics, Novartis, Otsuka America, Pamlab, Pfizer, Pfizer Canada, PGxHealth/Clinical Data, Pierre Fabre, Prexa, Propagate, Rexahn, Royalty, sanofi-aventis, Schering-Plough, Sepracor, Servier, Shire, SK, Sofinnova, Solvay, Vanda, VIVUS, Wyeth

Speakers Bureau: Merck, Pfizer, Schering-Plough, Wyeth

Content Editors

Meghan Grady

Director, Content Development, Neuroscience Education Institute, Carlsbad, CA

No other financial relationships to disclose.

Debbi Ann Morrissette, PhD

Adjunct Professor, Biological Sciences, California State University, San Marcos

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No other financial relationships to disclose.

Peer Reviewers

Ronnie Gorman Swift, MD

Professor and Associate Chairman, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla

Professor of Clinical Public Health, School of Public Health, New York; New York Medical College, Valhalla

Chief of Psychiatry and Associate Medical Director, Metropolitan Hospital Center, New York City

No other financial relationships to disclose.

Steven S. Simring, MD, MPH

Clinical Associate Professor, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York City

No other financial relationships to disclose.

Owen Nichols, PsyD, MBA, NHA, CPM, ABPP, ABMP

President and CEO, NorthKey Community Care, Covington, KY

No other financial relationships to disclose.

Cheryl Raleigh-DuRoff, MN, ARNP

Clinical Adviser, University of Washington School of Nursing, Seattle

Consultant, Valley Medical Center, Psychiatry and Counseling Center, Renton, WA

Psychiatric ARNP and Counselor in Private Practice, Seattle, WA

No other financial relationships to disclose.

Disclosed financial relationships have been reviewed by the Neuroscience Education Institute CME Advisory Board to resolve any potential conflicts of interest. All faculty and planning committee members have attested that their financial relationships do not affect their ability to present well-balanced, evidence-based content for this activity.

Disclosure of Off-Label Use

This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.


Participants have an implied responsibility to use the newly acquired information from this activity to enhance patient outcomes and their own professional development. The information presented in this educational activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this educational activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Primary references and full prescribing information should be consulted.

Sponsorship Information

Sponsored by the Neuroscience Education Institute.

Additionally sponsored by the American Society for the Advancement of Pharmacotherapy.


This activity is supported solely by the sponsor, Neuroscience Education Institute.


Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price


Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 4th Edition

ISBN: 9780511447990

$ 40
  Annual Subscription (Single User) Unit price


Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 4th Edition

ISBN: 9780511447983

$ 250
  Print + Online Access (One Year, Single User) Unit price


Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to

ISBN: 9781107587670

$ 294
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,

For the rest of the world, please contact:
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,